Use of stem cells and CD6 depleted stem cells for the induction of tolerance to allogenic transplants and/or for the treatment of leukemia

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8562968
APP PUB NO 20030232433A1
SERIAL NO

10410852

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the use of a composition containing stem cells as well as CD6 depleted stem cells for the induction of a tolerance to allogenic transplants and/or for the treatment of blood, immune, and cancer diseases for time-staggered application wherein first the stem cells are applied followed by application of the CD6 depleted stem cells. Furthermore, the present invention relates to a compound preparation containing stem cells and CD6 depleted stem cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)INGOLSTADTER LANDSTRASSE 1 NEUHERBERG D-85764

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Günther, Wolfgang Planegg, DE 3 4
Kolb, Hans Jochen München, DE 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 22, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00